Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US

Cancer Investigation

Volumn 28, Issue 9, 2010, Pages 963-968

  Cronin, Kathleen A ^a   Harlan, Linda C ^a   Dodd, Kevin W ^a   Abrams, Jeffrey S ^a   Ballard Barbash, Rachel ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Breast carcinoma; HER 2 neu; Population based study; SEER program

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; CANCER PATIENT; EARLY CANCER; ETHNICITY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; TUMOR VOLUME; UNITED STATES;

AFRICAN AMERICANS; ASIAN AMERICANS; BREAST NEOPLASMS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POPULATION SURVEILLANCE; PREVALENCE; RECEPTOR, ERBB-2; SEER PROGRAM; UNITED STATES;

EID: 77957988845     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.496759     Document Type: Article

References (17)

1. Romond, E. H.; Perez, E. A.; Bryant, J.; Suman, V. J.; Geyer, C. E. Jr.; Davidson, N. E.; Tan-Chiu, E.; Martino, S.; Paik, S.; Kaufman, P. A.; Swain, S. M.; Pisansky, T. M.; Fehrenbacher, L.; Kutteh, L. A.; Vogel, V. G.; Visscher, D. W.; Yothers, G.; Jenkins, R. B.; Brown, A. M.; Dakhil, S. R.; Mamounas, E. P.; Lingle, W. L.; Klein, P. M.; Ingle, J. N.; Wolmark, N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353, 1673-1684.
2. Piccart-Gebhart, M. J.; Procter, M.; Leyland-Jones, B.; Goldhirsch, A.; Untch, M.; Smith, I.; Gianni, L.; Baselga, J.; Bell, R.; Jackisch, C.; Cameron, D.; Dowsett, M.; Barrios, C. H.; Steger, G.; Huang, C. S.; Andersson, M.; Inbar, M.; Lichinitser, M.; Láng, I.; Nitz, U.; Iwata, H.; Thomssen, C.; Lohrisch, C.; Suter, T. M.; Rüschoff, J.; Suto, T.; Greatorex, V.; Ward, C.; Straehle, C.; McFadden, E.; Dolci, M. S.; Gelber, R. D.; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353, 1659-1672.
3. Borg, A.; Tandon, A. K.; Sigurdsson, H.; Clark, G. M.; Ferno, M.; Fuqua, S. A.; Killander, D.; McGuire, W. L. Her-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990, 50, 4332-4337.
4. Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235, 177-182.
5. Slamon, D. J.; Godolphin, W.; Jones, L. A.; Holt, J. A.; Wong, S. G.; Keith, D. E.; Levin, W. J.; Stuart, S. G.; Udove, J.; Ullrich, A.; Press, M. F Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244, 707-712.
6. Gusterson, B. A.; Gelber, R. D.; Goldhirsch, A.; Price, K. N.; Säve-Söderborgh, J.; Anbazhagan, R.; Styles, J.; Rudenstam, C. M.; Golouh, R.; Reed, R.; Martinez-Tello, F.; Tiltman, A.; Torhorst, J.; Grigolato, P.; Bettelheim, R.; Neville, A. M.; Birki, K.; Castiglione, Collins, M. J.; Lindtner, J. Prognostic importance of c-erbB 2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992, 10, 1049-1056.
7. Stark, A. T.; Claud, S.; Kapke, A.; Lu, M.; Linden, M.; Griggs, J. Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu. Cancer 2005, 104, 2189-2196.
8. Huang, H. J.; Neven, P.; Drijkoningen, M.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Berteloot, P.; Amant, F.; Christiaens, M. R.; Vergote, I. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related. Breast Cancer Res Treat 2005, 91, 81-87. (Pubitemid 40684941)
9. Huang, H. J.; Neven, P.; Drijkoningen, M.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Berteloot, P.; Amant, F.; Vergote, I.; Christiaens, MR. Association between tumour characteristics and HER-2/neu by immunohistochemisrty in 1362 women with primary operable breast cancer. J Clin Pathol 2005, 58, 611-616.
10. Huang, H. J.; Neven, P.; Drijkoningen, M.; Paridaens, R.; Wildiers, H.; Van Limbergen, E.; Berteloot, P.; Amant, F.; Vergote, I.; Christiaens, M. R. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. Ann Oncol 2005, 16, 1755-1761.
11. Konecny, G.; Pauletti, G.; Pegram, M.; Untch, M.; Dandekar, S.; Aguilar, Z.; Wilson, C.; Rong, H. M.; Bauerfeind, I.; Felber, M.; Wang, HJ.; Beryt, M.; Seshadri, R.; Hepp, H.; Slamon, DJ. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003, 95, 142-153. (Pubitemid 36193263)
12. Carey, LA.; Perou, CM.; Livasy, CA.; Dressler, L. G.; Cowan, D.; Conway, K.; Karaca, G.; Troester, M. A.; Tse, C. K.; Edmiston, S.; Deming, S. L.; Geradts, J.; Cheang, M. C.; Nielsen, TO.; Moorman, P. G.; Earp, H. S.; Millikan, RC. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA 2006, 295, 2492-2502.
13. Anderson, W. F.; Luo, S.; Chatterjee, N.; Rosenberg, P. S.; Matsuno, R. K.; Goodman, M. T.; et al. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat 2009, 113, 189-196.
14. SAS Institute Inc. SAS/STAT 9.1 User's Guide. Cary, NC: SAS Institute Inc, 2004.
15. Paik, S.; Bryant, J.; Tan-Chiu, E.; Romond, E.; Hiller, W.; Park, K.; et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002, 94, 852-854.
16. Perez, EA.; Suman, VJ.; Davidson, N. E.; Martino, S.; Kaufman, P. A.; Lingle, W. L.; Flynn, P. J.; Ingle, J. N.; Visscher, D.; Jenkins, R. B. HER2 testing by local, central and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 2006, 24, 3032-3038.
17. American Cancer Society. Cancer Facts and Figures 2006. Atlanta: American Cancer Society, 2006.